Ecnoglutide — compound monograph
GLP-1 receptor agonist (cAMP-biased, acylated). Phase 3. The Institute assesses 2 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Ecnoglutide
- Compound class
- GLP-1 receptor agonist (cAMP-biased, acylated)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- XW003 · ecnoglutide (INN)
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- not assigned in public records
- Molecular formula
- not published
- Average mass
- not published
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
The distinguishing design claim is signalling bias towards cyclic AMP with reduced beta-arrestin recruitment, intended to limit receptor desensitisation. The full sequence has not been placed in the public domain in a form the Institute treats as authoritative.
§1.4Assessment status
The Institute assesses Ecnoglutide across 2 indications and grades the strongest of them at low certainty. In confirmatory clinical development; no marketing authorisation.
Table 1. Assessed outcomes for Ecnoglutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −13.2 % body weight at 48 weeks with the highest dose versus −0.5 % with placebo in a Chinese phase 3 trial | Low | 1 |
| Type 2 diabetes mellitus | −1.8 % HbA1c reported at 24 weeks | Very low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.